Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
426 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mantle Cell Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Mantle Cell Lymphoma - Pipeline Review, H2 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Mantle Cell Lymphoma Overview 10 Therapeutics Development 11 Pipeline Products for Mantle Cell Lymphoma - Overview 11 Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 12 Mantle Cell Lymphoma - Therapeutics under Development by Companies 13 Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 17 Mantle Cell Lymphoma - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Mantle Cell Lymphoma - Products under Development by Companies 21 Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 26 Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 27 AB Science SA 27 AbbVie Inc 28 Acetylon Pharmaceuticals, Inc. 29 Actinium Pharmaceuticals, Inc. 30 Affimed GmbH 31 Amgen Inc. 32 Asana BioSciences, LLC 33 Astellas Pharma Inc. 34 Astex Pharmaceuticals, Inc. 35 Bayer AG 36 BeiGene, Ltd. 37 Bristol-Myers Squibb Company 38 Celgene Corporation 39 Cellular Biomedicine Group, Inc. 40 Eisai Co., Ltd. 41 Eli Lilly and Company 42 EpiZyme, Inc. 43 Gilead Sciences, Inc. 44 GlaxoSmithKline Plc 45 Hutchison MediPharma Limited 46 ImmunoGen, Inc. 47 Immunomedics, Inc. 48 Incyte Corporation 49 Inflection Biosciences Limited 50 Johnson & Johnson 51 Juno Therapeutics Inc. 52 Karyopharm Therapeutics, Inc. 53 Kite Pharma, Inc. 54 LFB S.A. 55 MacroGenics, Inc. 56 MedImmune, LLC 57 Merck & Co., Inc. 58 Merck KGaA 59 Millennium Pharmaceuticals Inc 60 MorphoSys AG 61 Nordic Nanovector ASA 62 Novartis AG 63 Onconova Therapeutics, Inc. 64 Oncternal Therapeutics, Inc. 65 Patrys Limited 66 Pharmacyclics, Inc. 67 Portola Pharmaceuticals, Inc. 68 Seattle Genetics, Inc. 69 Selvita S.A. 70 Stemline Therapeutics, Inc. 71 Takeda Pharmaceutical Company Limited 72 TG Therapeutics, Inc. 73 Vivolux AB 74 Mantle Cell Lymphoma - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Combination Products 76 Assessment by Target 77 Assessment by Mechanism of Action 82 Assessment by Route of Administration 87 Assessment by Molecule Type 89 Drug Profiles 91 (INCB-039110 + INCB-040093) - Drug Profile 91 13197 - Drug Profile 92 AB-8779 - Drug Profile 94 abexinostat hydrochloride - Drug Profile 95 acalabrutinib - Drug Profile 98 ACY-241 - Drug Profile 101 ACY-775 - Drug Profile 103 AFM-11 - Drug Profile 104 alisertib - Drug Profile 105 AMG-319 - Drug Profile 110 ASN-002 - Drug Profile 112 AT-7519 - Drug Profile 113 avicin d - Drug Profile 116 BC-8Y90 - Drug Profile 117 bendamustine hydrochloride - Drug Profile 118 Betalutin - Drug Profile 121 BGB-3111 - Drug Profile 125 BLyS-gel - Drug Profile 127 BMS-986016 - Drug Profile 128 buparlisib hydrochloride - Drug Profile 130 carfilzomib - Drug Profile 135 CBM-C19.1 - Drug Profile 147 CBM-C20.1 - Drug Profile 148 Cellular Immunotherapy for Oncology - Drug Profile 150 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 151 cerdulatinib - Drug Profile 152 copanlisib hydrochloride - Drug Profile 156 daratumumab - Drug Profile 160 denintuzumab mafodotin - Drug Profile 171 durvalumab - Drug Profile 174 E-7449 - Drug Profile 184 entospletinib - Drug Profile 185 epratuzumab - Drug Profile 187 EPZ-015666 - Drug Profile 194 HMPL-523 - Drug Profile 195 IBL-301 - Drug Profile 197 ibrutinib - Drug Profile 199 IGN-002 - Drug Profile 224 IMGN-529 - Drug Profile 226 IMMU-114 - Drug Profile 228 INA-01 - Drug Profile 230 INCB-40093 - Drug Profile 231 INCB-50465 - Drug Profile 232 inebilizumab - Drug Profile 233 inebilizumab + MEDI-0680 - Drug Profile 235 Iomab-B - Drug Profile 236 itacitinib adipate - Drug Profile 241 ixazomib citrate - Drug Profile 244 JCAR-014 - Drug Profile 253 JCAR-015 - Drug Profile 256 JCAR-017 - Drug Profile 261 JNJ-64052781 - Drug Profile 264 KTEC-19 - Drug Profile 266 LAM-002A - Drug Profile 273 M-7583 - Drug Profile 274 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 275 Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 276 MOR-208 - Drug Profile 277 ON-123300 - Drug Profile 282 ONC-201 - Drug Profile 283 OSU-2S - Drug Profile 287 PATLM-1 - Drug Profile 288 PCAR-019 - Drug Profile 290 pembrolizumab - Drug Profile 291 ramucirumab - Drug Profile 322 ribociclib succinate - Drug Profile 332 S-055746 - Drug Profile 337 sapanisertib - Drug Profile 338 SEL-120 - Drug Profile 341 SEL-12034 - Drug Profile 343 SEL-24B489 - Drug Profile 345 selinexor - Drug Profile 346 SGN-CD70A - Drug Profile 363 SL-101 - Drug Profile 364 spebrutinib besylate - Drug Profile 365 TAK-659 - Drug Profile 367 TGR-1202 - Drug Profile 368 tisagenlecleucel-T - Drug Profile 375 tretinoin - Drug Profile 380 ublituximab - Drug Profile 381 UC-961 - Drug Profile 388 venetoclax - Drug Profile 390 VLX-1570 - Drug Profile 399 vorinostat - Drug Profile 401 Mantle Cell Lymphoma - Dormant Projects 405 Mantle Cell Lymphoma - Discontinued Products 408 Mantle Cell Lymphoma - Product Development Milestones 409 Featured News & Press Releases 409 Appendix 418 Methodology 418 Coverage 418 Secondary Research 418 Primary Research 418 Expert Panel Validation 418 Contact Us 418 Disclaimer 419
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H2 2016 18 Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2016 24 Comparative Analysis by Late Stage Development, H2 2016 25 Comparative Analysis by Clinical Stage Development, H2 2016 26 Comparative Analysis by Early Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Development by Companies, H2 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2016 33 Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2016 34 Mantle Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016 35 Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 36 Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 37 Mantle Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016 38 Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2016 39 Mantle Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016 40 Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016 41 Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 42 Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2016 43 Mantle Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016 44 Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 45 Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016 46 Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 47 Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016 48 Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 49 Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016 50 Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 51 Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 52 Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016 53 Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016 54 Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016 55 Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016 56 Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016 57 Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016 58 Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 59 Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 60 Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2016 61 Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2016 62 Mantle Cell Lymphoma - Pipeline by MacroGenics, Inc., H2 2016 63 Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2016 64 Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 65 Mantle Cell Lymphoma - Pipeline by Merck KGaA, H2 2016 66 Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 67 Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016 68 Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 69 Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2016 70 Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016 71 Mantle Cell Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016 72 Mantle Cell Lymphoma - Pipeline by Patrys Limited, H2 2016 73 Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016 74 Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 75 Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 76 Mantle Cell Lymphoma - Pipeline by Selvita S.A., H2 2016 77 Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016 78 Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 79 Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016 80 Mantle Cell Lymphoma - Pipeline by Vivolux AB, H2 2016 81 Assessment by Monotherapy Products, H2 2016 82 Assessment by Combination Products, H2 2016 83 Number of Products by Stage and Target, H2 2016 85 Number of Products by Stage and Mechanism of Action, H2 2016 90 Number of Products by Stage and Route of Administration, H2 2016 95 Number of Products by Stage and Molecule Type, H2 2016 97 Mantle Cell Lymphoma - Dormant Projects, H2 2016 412 Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2016 413 Mantle Cell Lymphoma - Dormant Projects (Contd..2), H2 2016 414 Mantle Cell Lymphoma - Discontinued Products, H2 2016 415
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
